Skip to main content

Chikungunya

5
Pipeline Programs
7
Companies
6
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
2
0
1
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Vaccine
1100%
+ 7 programs with unclassified modality

Competitive Landscape

7 companies ranked by most advanced pipeline stage

Valneva
ValnevaAustria - Vienna
2 programs
1
1
ActivePhase 31 trial
VLA1553Phase 11 trial
Active Trials
NCT03382964Completed120Est. Jul 2019
NCT04650399Completed750Est. Feb 2024
Nordic Pharma
Nordic PharmaFrance - Paris
1 program
1
ChikungunyaPhase 2
Emergent BioSolutions
1 program
1
ChikungunyaPhase 2
Bharat Biotech
Bharat BiotechIndia - Hyderabad
1 program
1
Inactivated Chikungunya virus vaccine 20 mcgPhase 1Vaccine1 trial
Active Trials
NCT04603131Completed60Est. Jul 2018
Allied Medical
Allied MedicalMO - St. Louis
1 program
Venipuncture for blood drawN/A1 trial
Active Trials
NCT02463968Completed50Est. Jun 2017
Gylden Pharma
Gylden PharmaUK - Abingdon
1 program
PepGNP-ChikVPHASE_11 trial
Active Trials
NCT07394426Not Yet Recruiting40Est. May 2028
Bavarian Nordic
Bavarian NordicDenmark - Kvistgard
1 program
ChikungunyaPHASE_21 trial
Active Trials
NCT03992872Completed60Est. Jan 2021

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
ValnevaActive
Bavarian NordicChikungunya
Gylden PharmaPepGNP-ChikV
ValnevaVLA1553
Bharat BiotechInactivated Chikungunya virus vaccine 20 mcg
Allied MedicalVenipuncture for blood draw

Clinical Trials (6)

Total enrollment: 1,080 patients across 6 trials

NCT04650399ValnevaActive

A Multicenter Study to Evaluate Safety and Immunogenicity of a Live-attenuated Chikungunya Vaccine in Adolescents

Start: Jan 2022Est. completion: Feb 2024750 patients
Phase 3Completed
NCT03992872Bavarian NordicChikungunya

Phase 2 Open-label Study of Alum-adjuvanted Chikungunya Virus-like Particle Vaccine (PXVX0317)

Start: Nov 2019Est. completion: Jan 202160 patients
Phase 2Completed
NCT07394426Gylden PharmaPepGNP-ChikV

A Phase I Study of PepGNP-ChikV in Healthy Volunteers

Start: Aug 2026Est. completion: May 202840 patients
Phase 1Not Yet Recruiting
NCT03382964ValnevaVLA1553

Study to Assess the Safety and Immunogenicity of a Chikungunya Virus Vaccine Candidate (VLA1553) in Healthy Volunteers

Start: Mar 2018Est. completion: Jul 2019120 patients
Phase 1Completed
NCT04603131Bharat BiotechInactivated Chikungunya virus vaccine 20 mcg

Clinical Trial to Evaluate the Immunogenicity of Chikungunya Vaccine

Start: Apr 2017Est. completion: Jul 201860 patients
Phase 1Completed
NCT02463968Allied MedicalVenipuncture for blood draw

Chikungunya Arthritis in the Americas

Start: Aug 2016Est. completion: Jun 201750 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
7 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.